乳胶凝集测试套件市场，按测试类型（抗体检测、抗原测试）、感染类型（链球菌、葡萄球菌、埃希氏菌、沙门氏菌）、样本类型（血液、尿液、脑脊髓液）、最终用途- 全球预测2024 - 2032

在传染病日益普及的推动下，2024 年至 2032 年全球乳胶凝集测试套件市场复合年增长率将超过 6.5%。根据世界卫生组织2023年报告显示，2019年至2023年，全球结核病等传染病病例增加了10%，2023年新增病例约1,060万例。

随着全球传染病发病率的上升，越来越需要有效、可靠的诊断工具来及时检测和管理它们。乳胶凝集测试能够提供快速、准确的结果，这使得它们在对抗传染病爆发方面至关重要。对诊断准确性的更高需求导致了诊断技术的创新和更多产品的采用，从而加速了市场成长。

乳胶凝集测试套件市场根据测试类型、感染类型、样本类型、最终用途和地区进行分类。

到 2032 年，抗体检测领域将呈现出显着的复合年增长率，因其能够提供快速、精确且具成本效益的结果。这些测试对于识别和量化特异性抗体非常重要，这对于诊断和监测各种疾病至关重要。随着医疗保健提供者越来越关注个人化医疗和早期疾病检测，对高效抗体检测工具的需求激增。此外，对预防性医疗保健和常规筛检的日益重视，也导致人们对用于抗体检测的乳胶凝集检测试剂盒的兴趣日益浓厚。

由于人们越来越担心葡萄球菌的抗生素抗药性菌株，到 2032 年，葡萄球菌细分市场将占据相当大的市场份额。金黄色葡萄球菌，特别是抗甲氧西林金黄色葡萄球菌 MRSA，给治疗带来了巨大的挑战，因此准确、快速的检测对于有效的治疗至关重要。医疗机构正在优先考虑能够快速识别这些感染的工具，以确保及时介入和适当的治疗。这将推动对专门用于检测金黄色葡萄球菌感染的专用检测试剂盒的需求。

由于医疗基础设施投资的增加和诊断技术的进步，北美乳胶凝集测试套件市场在预测期内将出现显着的复合年增长率。对早期疾病检测和个人化医疗的高度重视刺激了对准确、快速诊断工具的需求。此外，人们对感染控制和预防性医疗措施的认识不断提高，也导致了产品需求的成长。医疗保健产业着重采用创新、高效的诊断解决方案，这有利于研究经费和技术进步，从而推动该地区的市场成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 传染病和自体免疫疾病盛行率上升
    • 对即时检测 (POCT) 的需求不断增加
    • 技术创新
    • 提高认识和筛检计划
  • 产业陷阱与挑战
    • 严格的监管要求
• 成长潜力分析
• 技术景观
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 竞争定位矩阵
• 战略展望矩阵

第 5 章：市场估计与预测：按测试类型，2021 - 2032 年

• 主要趋势
• 抗体检测
• 抗原检测

第 6 章：市场估计与预测：按感染类型，2021 - 2032

• 主要趋势
• 链球菌属
• 金黄色葡萄球菌
• 大肠桿菌
• 沙门氏菌属
• 其他感染类型

第 7 章：市场估计与预测：按样本类型，2021 - 2032

• 主要趋势
• 血
• 尿
• 脑脊髓液
• 其他样品类型

第 8 章：市场估计与预测：按最终用途，2021 - 2032 年

• 主要趋势
• 医院
• 诊断实验室
• 学术及研究机构

第 9 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 10 章：公司简介

• Atlas Medical GmbH
• Arlington Scientific, Inc
• Bio-Rad Laboratories, Inc.
• bioMerieuxSA
• Biotium
• Creative Diagnostics
• Cardinal Health, Inc.
• Eurofins Scientific Group
• Hardy plc
• HiMedia Laboratories
• Liofilchem S.r.l.
• Novacyt Group
• PerkinElmer, Inc.
• Pro Lab Diagnostics
• Thermo Fisher Scientific Inc.

Global Latex Agglutination Test Kits Market will experience over 6.5% CAGR from 2024 to 2032, thrusted by the growing prevalence of infectious diseases. According to the WHO reports in 2023, global cases of infectious diseases such as tuberculosis TB increased by 10% from 2019 to 2023, reaching approximately 10.6 million new cases in 2023.

As the incidence rate of infectious ailment rises globally, there is an increasing need for effective and reliable diagnostic tools to detect and manage them promptly. The ability of latex agglutination tests to deliver rapid and accurate results makes them crucial in the fight against infectious outbreaks. This heightened demand for diagnostic accuracy leads to innovation in diagnostic technology and greater product adoption, accelerating market growth.

The latex agglutination test kits market is categorized based on test type, infection type, sample type, end-use, and region.

The antibody detection segment will exhibit a noticeable CAGR through 2032, catapulted by its ability to offer quick, precise, and cost-effective results. These tests are important for identifying and quantifying specific antibodies, which is crucial in diagnosing and monitoring various diseases. As healthcare providers increasingly focus on personalized medicine and early disease detection, the need for efficient antibody detection tools has surged. Additionally, the growing emphasis on preventive healthcare and routine screening contributes to the heightened interest in latex agglutination test kits for antibody detection.

The staphylococcus segment will grab a substantial market share by 2032, owing to the growing concern over antibiotic-resistant strains of this bacterium. Staphylococcus aureus, particularly methicillin-resistant Staphylococcus aureus MRSA, poses significant treatment challenges, making accurate and rapid detection essential for effective management. Healthcare settings are prioritizing tools that swiftly identify these infections to ensure timely intervention and appropriate treatment. This will drive the demand for specialized test kits tailored to detect Staphylococcus aureus infections.

North America latex agglutination test kits market will register a prominent CAGR during the forecast period, because of increased investment in healthcare infrastructure and advancements in diagnostic technology. The strong emphasis on early disease detection and personalized medicine spurs the need for accurate and rapid diagnostic tools. Additionally, heightened awareness of infection control and preventive healthcare measures contributes to the rising product demand. The focus in healthcare sector on adopting innovative and efficient diagnostic solutions is favoring research funding and technological advancements, thereby propelling the market growth in the region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of infectious and autoimmune diseases
    • 3.2.1.2 Increasing demand for point-of-care testing (POCT)
    • 3.2.1.3 Technological innovations
    • 3.2.1.4 Increasing awareness and screening programs
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory requirements
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Antibody detection
• 5.3 Antigen testing

Chapter 6 Market Estimates and Forecast, By Infection Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Streptococcus
• 6.3 Staphylococcus Aureus
• 6.4 Escherichia Coli
• 6.5 Salmonella Spp.
• 6.6 Other infection types

Chapter 7 Market Estimates and Forecast, By Sample Type, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Blood
• 7.3 Urine
• 7.4 Cerebrospinal fluid
• 7.5 Other sample types

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Diagnostic laboratories
• 8.4 Academic and research institutes

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Atlas Medical GmbH
• 10.2 Arlington Scientific, Inc
• 10.3 Bio-Rad Laboratories, Inc.
• 10.4 bioMerieuxSA
• 10.5 Biotium
• 10.6 Creative Diagnostics
• 10.7 Cardinal Health, Inc.
• 10.8 Eurofins Scientific Group
• 10.9 Hardy plc
• 10.10 HiMedia Laboratories
• 10.11 Liofilchem S.r.l.
• 10.12 Novacyt Group
• 10.13 PerkinElmer, Inc.
• 10.14 Pro Lab Diagnostics
• 10.15 Thermo Fisher Scientific Inc.